Market Research Report
Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class and Therapy Type : Global Opportunity Analysis and Industry Forecast, 2021-2030
|Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class and Therapy Type : Global Opportunity Analysis and Industry Forecast, 2021-2030|
Published: January 25, 2022
Allied Market Research
Content info: 216 Pages
Delivery time: 2-3 business days
The global benign prostatic hyperplasia therapeutics market was valued at $5,697.70 million in 2020, and is estimated to reach $9,391.50 million by 2030, growing at a CAGR of 5.00% from 2021 to 2030.
The prostate is a walnut-sized gland that surrounds the urethra in the male reproductive system. The main function of this gland is to secrete a fluid, which mixes with the fluids from other glands and sperm cells from the testicles to generate semen. Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland. It is also called benign prostatic hypertrophy or benign prostatic obstruction. As a man gets older, his prostate goes through two major growth stages. The first happens when the prostate doubles in size throughout adolescence. The second stage of development begins at the age of 25 and lasts for the rest of a man's life. The BPH is common during the second growth phase.
As the prostate gland grows larger, it presses against and pinches the urethra. The bladder's lining thickens. It prevents urine from flowing freely from the bladder, resulting in nighttime urination, urinary hesitation, trouble starting to urinate, a weak urine stream or a stream that stops and begins, dribbling at the end of urination, and a sense of urgency to urinate. The bladder's ability to empty completely may weaken over time, causing urinary retention by leaving some urine in the bladder. Many of the symptoms of benign prostatic hyperplasia are caused by urethral constriction and urine retention, or the inability to empty the bladder entirely. Because of symptoms like urine leakage and nocturia, BPH has a substantial impact on the patient's quality of life. If untreated for a long duration, it results in more serious health issues, such as bladder damage, bladder stones, kidney damage, and urinary tract infections (UTIs). Moreover, lower urinary tract symptoms (LUTS) are becoming more common in both men and women as they get older. LUTS is frequently associated with benign prostatic hyperplasia in men (BPH).
This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 50 and above. For instance, according to The Administration for Community Living, which includes the Administration on Aging, is an operating division of the U.S. Department of Health and Human Services. In 2019, the American population aged above 65 was 54.1 million among which about 24.1million were men. The overall population aged 65 and older increased from 39.6 million in 2009 to 54.1 million in 2019 a 36% increase and is projected to reach 94.7 million in 2060. By 2040, there will be about 80.8 million older persons, more than twice as many as in 2000. Thus, such increase in older population especially in males is anticipated to drive the growth of the market. In addition, according to The Official Foundation of the American Urological Association about half of all men aged between 51 and 60 years and up to 90% of men over age 80 have BPH.
The other factors boosting the market growth include increase in unhealthy lifestyle among the population, growth in awareness related to urological disorders, early diagnosis of the medical condition, rise in prostate cancer cases and rise in the number of global benign prostatic hyperplasia patients. In addition, a family history of erectile dysfunction, obesity, type 2 diabetes, insufficient exercise, and erectile dysfunction are all risk factors of BPH. The alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor therapeutic class of drugs are the majorly used. Furthermore, antimuscarinics, anticholinergic agents, and beta 3 adrenoreceptor are also used.
However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.
The global benign prostatic hyperplasia therapeutics market is segmented on the basis of therapeutic class, therapy, and region. On the basis of therapeutic class, the market is categorized into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. By therapy, the market is bifurcated into mono drug therapy and combination drug therapy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).
The major players profiled in the report are Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Limited.